COPENHAGEN, OCTOBER 09, 2018 - Dr. Rasmus Toft-Kehler, Chief Executive Officer of AntibioTx, announced this week in Copenhagen that the company has officially changed its name to UNION therapeutics as of October 5, 2018.
”The new company name – UNION – reflects recent progress on the technology platform and expansion of expertise”, explained Dr. Toft-Kehler, and commented: “Our chemistry platform has provided compounds with very interesting immunological properties in combination with antimicrobial activity. The unique properties of our compounds will enable us to develop innovative treatments across a broad spectrum of diseases” and further adds “the expansion into immunology represents a new era for the company with great prospects for both patients and society”.
UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. UNION will initially focus on the treatment of inflammatory skin diseases, however, the chemistry platform and its versatile new modes of action is expected to be applicable across a wide range of diseases. The leadership team of UNION has invented and successfully developed more than 10 FDA-approved medicines. In 2017, these medicines saved thousands of lives and generated revenues of more than 5 Billion USD. UNION is headquartered in Copenhagen (Denmark) with a US subsidiary and a global team.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutic A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.